세계의 환각제 시장 : 산업 규모, 점유율, 동향, 기회＆예측, 약물 유형별, 용도별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드:1698006
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 186 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
환각제 세계 시장 규모는 2024년 45억 5,000만 달러에 달했고, 2030년까지 예측 기간 동안 연평균 10.55%의 괄목할만한 성장이 예상됩니다.
세계 환각제 시장은 임상연구의 눈부신 발전, 규제 프레임워크의 진화, 사회적 인식의 변화 등에 힘입어 새로운 관심 증가와 확대가 이루어지고 있습니다. 특히 우울증, 불안장애, 외상 후 스트레스 장애(PTSD)와 같은 정신질환의 유병률이 증가함에 따라 혁신적이고 효과적인 치료 솔루션에 대한 수요가 급증하고 있습니다. 환각제 기반 치료제는 기존 항우울제에 대한 파괴적인 대안으로 각광받고 있으며, 임상시험에서 빠른 효과 발현과 지속적인 효능을 입증하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
45억 5,000만 달러
시장 규모 : 2030년
83억 2,000만 달러
CAGR : 2025-2030년
10.55%
급성장 부문
병원 약국
최대 시장
북미
시장 성장은 정신 건강에 대한 인식 증가, 진보적인 정책 개혁, 환각제의 의학적 유용성을 뒷받침하는 과학적 증거 증가로 인해 더욱 가속화되고 있습니다. 제약회사, 생명공학 기업 및 연구기관 간의 전략적 파트너십은 의약품 개발 파이프라인을 가속화하고 정신의학 분야에서 환각제 화합물이 주류에 통합될 수 있는 가능성을 높이고 있습니다. 규제 당국의 승인이 확대되고 연구개발에 대한 투자가 강화됨에 따라 환각제 시장은 장기적으로 크게 성장할 준비가 되어 있습니다.
Global Psychedelic Drug Market was valued at USD 4.55 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 10.55% through 2030. The global psychedelic drug market is witnessing a renewed surge in interest and expansion, fueled by significant advancements in clinical research, evolving regulatory frameworks, and shifting societal perceptions. The rising prevalence of mental health disorders-particularly depression, anxiety, and post-traumatic stress disorder (PTSD)-has created an urgent demand for innovative and effective treatment solutions. Psychedelic-based therapeutics are gaining traction as a disruptive alternative to conventional antidepressants, demonstrating both rapid onset and sustained efficacy in clinical trials.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 4.55 Billion
Market Size 2030
USD 8.32 Billion
CAGR 2025-2030
10.55%
Fastest Growing Segment
Hospital Pharmacies
Largest Market
North America
Market growth is being further catalyzed by increasing mental health awareness, progressive policy reforms, and a growing body of scientific evidence supporting the medical utility of psychedelics. Strategic partnerships between pharmaceutical companies, biotech firms, and research institutions are accelerating drug development pipelines, positioning psychedelic compounds for potential mainstream integration within psychiatric care. As regulatory approvals expand and investment in research and development intensifies, the psychedelic drug market is poised for substantial long-term growth.
Key Market Drivers
Rising Prevalence of Mental Health Disorders
The increasing global prevalence of mental health disorders is one of the most significant catalysts driving the growth of the psychedelic drugs market. As traditional treatment approaches struggle to meet the rising demand for effective solutions, psychedelic-assisted therapies are emerging as a disruptive innovation in psychiatric care. The burden of mental health disorders has reached unprecedented levels, with conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) affecting millions worldwide. According to data from the World Health Organization (WHO), depression affects more than 284 million individuals worldwide, making it one of the most widespread mental health conditions. Similarly, over 264 million people are impacted by anxiety disorders, highlighting the growing demand for effective mental health interventions. Despite these alarming statistics, conventional treatments-including selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT)-often produce suboptimal results, with many patients experiencing delayed symptom relief, treatment resistance, or severe side effects. This growing treatment gap has created a strong demand for innovative therapies, positioning psychedelics as a viable alternative.
Key Market Challenges
Regulatory Hurdles
Perhaps the most significant challenge facing the psychedelic drug market is the complex and evolving regulatory landscape. Many psychedelics are classified as controlled substances due to their historical association with recreational use and concerns about safety and abuse potential. Navigating these regulations can be a lengthy and expensive process, often requiring years of clinical trials and regulatory approvals.
Key Market Players
Jazz Pharmaceuticals PLC
NeonMind Biosciences Inc.
Cybin Inc.
Pfizer Inc
Numinus Wellness Inc
Mind Medicine Inc
PharmaTher Holdings Ltd
NRX Pharmaceuticals Inc
Seelos Therapeutics Inc
Revive Therapeutics Inc
Report Scope:
In this report, the Global Psychedelic Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Psychedelic Drug Market, By Drug Type:
Lysergic Acid Diethylamide
Gamma Hydroxybutyric Acid
Ketamine
Psilocybin
Others
Psychedelic Drug Market, By Application:
Treatment-Resistant Depression
Opiate Addiction
Post-Traumatic Stress Disorder
Narcolepsy
Panic Disorders
Others
Psychedelic Drug Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Psychedelic Drug Market, By Region:
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia-Pacific
China
Japan
India
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Psychedelic Drug Market.
Available Customizations:
Global Psychedelic Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Psychedelic Drug Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
